Drug Search Results
More Filters [+]

Azeliragon

Alternative Names: azeliragon, ttp488, pf-04494700
Latest Update: 2024-09-19
Latest Update Note: Clinical Trial Update

Product Description

Azeliragon is an oral, small-molecule inhibitor of RAGE, a cell-surface receptor of the immunoglobulin superfamily. (Sourced from: https://www.alzforum.org/therapeutics/azeliragon)

Mechanisms of Action: RAGE Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation:
Orphan Drug - Glioblastoma
Orphan Drug - Pancreatic Cancer *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: vTv
Company Location: HIGH POINT NC 27265
Company CEO: Paul J. Sekhri
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Azeliragon

Countries in Clinic: Spain, United States

Active Clinical Trial Count: 5

Highest Development Phases

Phase 2: Brain Cancer|Glioblastoma|Pancreatic Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2022-002801-36

P2

Active, not recruiting

Glioblastoma

2026-03-01

ADORATION

P2

Recruiting

Brain Cancer

2025-10-01

CAN-201 MPC

P2

Recruiting

Pancreatic Cancer

2025-02-01

57%

CAN 201

P2

Recruiting

Glioblastoma

2024-12-01

57%

Recent News Events